We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teladoc (TDOC) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Teladoc (TDOC - Free Report) closed at $218.56 in the latest trading session, marking a -1.47% move from the prior day. This move lagged the S&P 500's daily loss of 0.34%. Elsewhere, the Dow lost 0.5%, while the tech-heavy Nasdaq lost 0.73%.
Coming into today, shares of the telehealth services provider had gained 15.5% in the past month. In that same time, the Medical sector gained 5.8%, while the S&P 500 gained 5.71%.
TDOC will be looking to display strength as it nears its next earnings release, which is expected to be July 29, 2020. On that day, TDOC is projected to report earnings of -$0.23 per share, which would represent year-over-year growth of 43.9%. Our most recent consensus estimate is calling for quarterly revenue of $220.22 million, up 69.04% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$1.12 per share and revenue of $845.38 million. These totals would mark changes of +18.84% and +52.79%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for TDOC. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.59% higher. TDOC currently has a Zacks Rank of #2 (Buy).
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 105, putting it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teladoc (TDOC) Dips More Than Broader Markets: What You Should Know
Teladoc (TDOC - Free Report) closed at $218.56 in the latest trading session, marking a -1.47% move from the prior day. This move lagged the S&P 500's daily loss of 0.34%. Elsewhere, the Dow lost 0.5%, while the tech-heavy Nasdaq lost 0.73%.
Coming into today, shares of the telehealth services provider had gained 15.5% in the past month. In that same time, the Medical sector gained 5.8%, while the S&P 500 gained 5.71%.
TDOC will be looking to display strength as it nears its next earnings release, which is expected to be July 29, 2020. On that day, TDOC is projected to report earnings of -$0.23 per share, which would represent year-over-year growth of 43.9%. Our most recent consensus estimate is calling for quarterly revenue of $220.22 million, up 69.04% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$1.12 per share and revenue of $845.38 million. These totals would mark changes of +18.84% and +52.79%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for TDOC. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.59% higher. TDOC currently has a Zacks Rank of #2 (Buy).
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 105, putting it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.